Immunophilin-loaded erythrocytes as a new delivery strategy for immunosuppressive drugs

Sara Biagiotti, Luigia Rossi, Marzia Bianchi, Elisa Giacomini, Francesca Pierigè, Giordano Serafini, Pier Giulio Conaldi, Mauro Magnani

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Cyclosporine A (CsA) and tacrolimus (also known as FK506) are natural compounds with immunosuppressive activity that have improved the outcome of organ transplantation. Unfortunately, both drugs are characterised by high pharmacokinetic variability, poor bioavailability and high toxicity. Until now, no optimal method to deliver immunosuppressant drugs into circulation has been developed. Here we propose the use of engineered erythrocytes as a drug delivery system for the release of immunosuppressants in circulation in order to modify their pharmacokinetic and restrain toxic effects. After administration, FK506 and CsA mainly distribute within erythrocytes owing to the presence into these cells of immunophilins that bind the drugs with very high affinity (FKBP12 for FK506 and cyclophilin A for CsA); therefore, a new strategy aimed to increase the amount of FK506/CsA carried by erythrocytes by increasing the intra-erythrocytic concentration of the respective binding proteins has been developed. We manufactured recombinant forms of human FKBP12 and cyclophilin A to be loaded into RBC through a hypotonic dialysis and isotonic resealing procedure. Erythrocytes loaded with 3.5 ± 1.3, 7.5 ± 3.1 and 15.5 ± 0.4 nmol FKBP12 were able to bind 3.5 ± 1.5, 6.0 ± 1.9 and 11.4 ± 2.9 μg FK506 per millilitre RBC, respectively, while RBC loaded with 4.0 ± 0.6, 5.0 ± 0.8 and 15.9 ± 2.4 nmol of cyclophilin A could bind 8.9 ± 3.4, 12.2 ± 3.5 and 17.0 ± 3.2 μg CsA. Thus, both engineered RBC were demonstrated able to bind up to an order of magnitude more drug than corresponding native erythrocytes (1.0 ± 0.3 μg FK506 and 3.2 ± 0.3 μg CsA). Moreover, FK506 released from FKBP12-RBC is able to be up-taken by T lymphocytes and inhibit IL-2 expression in vitro as free administered drug. In summary, our results indicate that diffusible immunosuppressants could be entrapped into red cells (thanks to the loading of the respective target protein) and suggest that immunophilin-loaded RBC could be employed as potential delivery system for immunosuppressive agents.

Original languageEnglish
Pages (from-to)306-313
Number of pages8
JournalJournal of Controlled Release
Volume154
Issue number3
DOIs
Publication statusPublished - Sep 25 2011

Fingerprint

Immunophilins
Tacrolimus
Immunosuppressive Agents
Erythrocytes
Tacrolimus Binding Protein 1A
Cyclosporine
Cyclophilin A
Pharmaceutical Preparations
Pharmacokinetics
Poisons
Organ Transplantation
Drug Delivery Systems
Biological Availability
Interleukin-2
Dialysis
Carrier Proteins
T-Lymphocytes

Keywords

  • Cyclophilin A
  • Cyclosporine A
  • Drug delivery
  • Erythrocytes
  • FKBP12
  • Tacrolimus

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Biagiotti, S., Rossi, L., Bianchi, M., Giacomini, E., Pierigè, F., Serafini, G., ... Magnani, M. (2011). Immunophilin-loaded erythrocytes as a new delivery strategy for immunosuppressive drugs. Journal of Controlled Release, 154(3), 306-313. https://doi.org/10.1016/j.jconrel.2011.05.024

Immunophilin-loaded erythrocytes as a new delivery strategy for immunosuppressive drugs. / Biagiotti, Sara; Rossi, Luigia; Bianchi, Marzia; Giacomini, Elisa; Pierigè, Francesca; Serafini, Giordano; Conaldi, Pier Giulio; Magnani, Mauro.

In: Journal of Controlled Release, Vol. 154, No. 3, 25.09.2011, p. 306-313.

Research output: Contribution to journalArticle

Biagiotti, S, Rossi, L, Bianchi, M, Giacomini, E, Pierigè, F, Serafini, G, Conaldi, PG & Magnani, M 2011, 'Immunophilin-loaded erythrocytes as a new delivery strategy for immunosuppressive drugs', Journal of Controlled Release, vol. 154, no. 3, pp. 306-313. https://doi.org/10.1016/j.jconrel.2011.05.024
Biagiotti S, Rossi L, Bianchi M, Giacomini E, Pierigè F, Serafini G et al. Immunophilin-loaded erythrocytes as a new delivery strategy for immunosuppressive drugs. Journal of Controlled Release. 2011 Sep 25;154(3):306-313. https://doi.org/10.1016/j.jconrel.2011.05.024
Biagiotti, Sara ; Rossi, Luigia ; Bianchi, Marzia ; Giacomini, Elisa ; Pierigè, Francesca ; Serafini, Giordano ; Conaldi, Pier Giulio ; Magnani, Mauro. / Immunophilin-loaded erythrocytes as a new delivery strategy for immunosuppressive drugs. In: Journal of Controlled Release. 2011 ; Vol. 154, No. 3. pp. 306-313.
@article{6afc9e7ec87b4339a6f82171404dae07,
title = "Immunophilin-loaded erythrocytes as a new delivery strategy for immunosuppressive drugs",
abstract = "Cyclosporine A (CsA) and tacrolimus (also known as FK506) are natural compounds with immunosuppressive activity that have improved the outcome of organ transplantation. Unfortunately, both drugs are characterised by high pharmacokinetic variability, poor bioavailability and high toxicity. Until now, no optimal method to deliver immunosuppressant drugs into circulation has been developed. Here we propose the use of engineered erythrocytes as a drug delivery system for the release of immunosuppressants in circulation in order to modify their pharmacokinetic and restrain toxic effects. After administration, FK506 and CsA mainly distribute within erythrocytes owing to the presence into these cells of immunophilins that bind the drugs with very high affinity (FKBP12 for FK506 and cyclophilin A for CsA); therefore, a new strategy aimed to increase the amount of FK506/CsA carried by erythrocytes by increasing the intra-erythrocytic concentration of the respective binding proteins has been developed. We manufactured recombinant forms of human FKBP12 and cyclophilin A to be loaded into RBC through a hypotonic dialysis and isotonic resealing procedure. Erythrocytes loaded with 3.5 ± 1.3, 7.5 ± 3.1 and 15.5 ± 0.4 nmol FKBP12 were able to bind 3.5 ± 1.5, 6.0 ± 1.9 and 11.4 ± 2.9 μg FK506 per millilitre RBC, respectively, while RBC loaded with 4.0 ± 0.6, 5.0 ± 0.8 and 15.9 ± 2.4 nmol of cyclophilin A could bind 8.9 ± 3.4, 12.2 ± 3.5 and 17.0 ± 3.2 μg CsA. Thus, both engineered RBC were demonstrated able to bind up to an order of magnitude more drug than corresponding native erythrocytes (1.0 ± 0.3 μg FK506 and 3.2 ± 0.3 μg CsA). Moreover, FK506 released from FKBP12-RBC is able to be up-taken by T lymphocytes and inhibit IL-2 expression in vitro as free administered drug. In summary, our results indicate that diffusible immunosuppressants could be entrapped into red cells (thanks to the loading of the respective target protein) and suggest that immunophilin-loaded RBC could be employed as potential delivery system for immunosuppressive agents.",
keywords = "Cyclophilin A, Cyclosporine A, Drug delivery, Erythrocytes, FKBP12, Tacrolimus",
author = "Sara Biagiotti and Luigia Rossi and Marzia Bianchi and Elisa Giacomini and Francesca Pierig{\`e} and Giordano Serafini and Conaldi, {Pier Giulio} and Mauro Magnani",
year = "2011",
month = "9",
day = "25",
doi = "10.1016/j.jconrel.2011.05.024",
language = "English",
volume = "154",
pages = "306--313",
journal = "Journal of Controlled Release",
issn = "0168-3659",
publisher = "Elsevier B.V.",
number = "3",

}

TY - JOUR

T1 - Immunophilin-loaded erythrocytes as a new delivery strategy for immunosuppressive drugs

AU - Biagiotti, Sara

AU - Rossi, Luigia

AU - Bianchi, Marzia

AU - Giacomini, Elisa

AU - Pierigè, Francesca

AU - Serafini, Giordano

AU - Conaldi, Pier Giulio

AU - Magnani, Mauro

PY - 2011/9/25

Y1 - 2011/9/25

N2 - Cyclosporine A (CsA) and tacrolimus (also known as FK506) are natural compounds with immunosuppressive activity that have improved the outcome of organ transplantation. Unfortunately, both drugs are characterised by high pharmacokinetic variability, poor bioavailability and high toxicity. Until now, no optimal method to deliver immunosuppressant drugs into circulation has been developed. Here we propose the use of engineered erythrocytes as a drug delivery system for the release of immunosuppressants in circulation in order to modify their pharmacokinetic and restrain toxic effects. After administration, FK506 and CsA mainly distribute within erythrocytes owing to the presence into these cells of immunophilins that bind the drugs with very high affinity (FKBP12 for FK506 and cyclophilin A for CsA); therefore, a new strategy aimed to increase the amount of FK506/CsA carried by erythrocytes by increasing the intra-erythrocytic concentration of the respective binding proteins has been developed. We manufactured recombinant forms of human FKBP12 and cyclophilin A to be loaded into RBC through a hypotonic dialysis and isotonic resealing procedure. Erythrocytes loaded with 3.5 ± 1.3, 7.5 ± 3.1 and 15.5 ± 0.4 nmol FKBP12 were able to bind 3.5 ± 1.5, 6.0 ± 1.9 and 11.4 ± 2.9 μg FK506 per millilitre RBC, respectively, while RBC loaded with 4.0 ± 0.6, 5.0 ± 0.8 and 15.9 ± 2.4 nmol of cyclophilin A could bind 8.9 ± 3.4, 12.2 ± 3.5 and 17.0 ± 3.2 μg CsA. Thus, both engineered RBC were demonstrated able to bind up to an order of magnitude more drug than corresponding native erythrocytes (1.0 ± 0.3 μg FK506 and 3.2 ± 0.3 μg CsA). Moreover, FK506 released from FKBP12-RBC is able to be up-taken by T lymphocytes and inhibit IL-2 expression in vitro as free administered drug. In summary, our results indicate that diffusible immunosuppressants could be entrapped into red cells (thanks to the loading of the respective target protein) and suggest that immunophilin-loaded RBC could be employed as potential delivery system for immunosuppressive agents.

AB - Cyclosporine A (CsA) and tacrolimus (also known as FK506) are natural compounds with immunosuppressive activity that have improved the outcome of organ transplantation. Unfortunately, both drugs are characterised by high pharmacokinetic variability, poor bioavailability and high toxicity. Until now, no optimal method to deliver immunosuppressant drugs into circulation has been developed. Here we propose the use of engineered erythrocytes as a drug delivery system for the release of immunosuppressants in circulation in order to modify their pharmacokinetic and restrain toxic effects. After administration, FK506 and CsA mainly distribute within erythrocytes owing to the presence into these cells of immunophilins that bind the drugs with very high affinity (FKBP12 for FK506 and cyclophilin A for CsA); therefore, a new strategy aimed to increase the amount of FK506/CsA carried by erythrocytes by increasing the intra-erythrocytic concentration of the respective binding proteins has been developed. We manufactured recombinant forms of human FKBP12 and cyclophilin A to be loaded into RBC through a hypotonic dialysis and isotonic resealing procedure. Erythrocytes loaded with 3.5 ± 1.3, 7.5 ± 3.1 and 15.5 ± 0.4 nmol FKBP12 were able to bind 3.5 ± 1.5, 6.0 ± 1.9 and 11.4 ± 2.9 μg FK506 per millilitre RBC, respectively, while RBC loaded with 4.0 ± 0.6, 5.0 ± 0.8 and 15.9 ± 2.4 nmol of cyclophilin A could bind 8.9 ± 3.4, 12.2 ± 3.5 and 17.0 ± 3.2 μg CsA. Thus, both engineered RBC were demonstrated able to bind up to an order of magnitude more drug than corresponding native erythrocytes (1.0 ± 0.3 μg FK506 and 3.2 ± 0.3 μg CsA). Moreover, FK506 released from FKBP12-RBC is able to be up-taken by T lymphocytes and inhibit IL-2 expression in vitro as free administered drug. In summary, our results indicate that diffusible immunosuppressants could be entrapped into red cells (thanks to the loading of the respective target protein) and suggest that immunophilin-loaded RBC could be employed as potential delivery system for immunosuppressive agents.

KW - Cyclophilin A

KW - Cyclosporine A

KW - Drug delivery

KW - Erythrocytes

KW - FKBP12

KW - Tacrolimus

UR - http://www.scopus.com/inward/record.url?scp=80052532218&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052532218&partnerID=8YFLogxK

U2 - 10.1016/j.jconrel.2011.05.024

DO - 10.1016/j.jconrel.2011.05.024

M3 - Article

C2 - 21640771

AN - SCOPUS:80052532218

VL - 154

SP - 306

EP - 313

JO - Journal of Controlled Release

JF - Journal of Controlled Release

SN - 0168-3659

IS - 3

ER -